Sign in
Subscribe
    • Stock Lists
      arrow_drop_down
      • Longevity Stocks
      • COVID-19 Stocks
    • Longevity Trial Tracker
    • Newsletter
    • Resources
      arrow_drop_down
      • Events
      • Supporters
    • About
    Subscribe

    Longeveron (LGVN)

    mesenchymal stem cell therapies

    • Profile
    • prev
    • next
    • Bookmark
    • Website
    • Share
    • prev
    • next
    $LGVN
    $3.99
    $0.0100
    -0.25%

    Marketcap: $83.86M
    Volume: 14.94K

    Longeveron Inc.
    Symbol: LGVN
    Employees: 18
    Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
    Website https://www.longeveron.com

    LongevityMarketcap.com 2021.

      • Facebook
      • Twitter
      • WhatsApp
      • Telegram
      • LinkedIn
      • Tumblr
      • VKontakte
      • Mail
      • Copy link